Free Access
Issue
Med Sci (Paris)
Volume 30, Number 6-7, Juin–Juillet 2014
Page(s) 683 - 687
Section Forum
DOI https://doi.org/10.1051/medsci/20143006021
Published online 11 July 2014
  1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011 ; 144 : 646–674. [CrossRef] [PubMed] [Google Scholar]
  2. Bozic I, Antal T, Ohtsuki H, et al. Accumulation of driver and passenger mutations during tumour progression. Proc Natl Acad Sci USA 2010 ; 107 : 18545–18550. [CrossRef] [Google Scholar]
  3. Versteeg R. Cancer: tumours outside the mutation box. Nature 2014 ; 506 : 438–439. [CrossRef] [PubMed] [Google Scholar]
  4. Sakaguchi H, Okuno Y, Muramatsu H, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet 2013 ; 45 : 937–941. [CrossRef] [PubMed] [Google Scholar]
  5. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature 2013 ; 502 : 333–339. [CrossRef] [PubMed] [Google Scholar]
  6. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013 ; 500 : 415–421. [CrossRef] [PubMed] [Google Scholar]
  7. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014 ; 505 : 495–501. [CrossRef] [PubMed] [Google Scholar]
  8. Nik-Zainal S, Alexandrov LB, Wedge DC, et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012 ; 149 : 979–993. [CrossRef] [PubMed] [Google Scholar]
  9. Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011 ; 144 : 27–40. [CrossRef] [PubMed] [Google Scholar]
  10. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988 ; 48 : 7067–7071. [PubMed] [Google Scholar]
  11. Luebeck EG. Cancer: genomic evolution of metastasis. Nature 2010 ; 467 : 1053–1055. [CrossRef] [PubMed] [Google Scholar]
  12. Wong TN, Ramsingh G, Young A, et al. The role of early TP53 mutations on the evolution of therapy-related AML. 55th ASH Annual Meeting, New Orleans, December 7–10, 2013, abstract 5. [Google Scholar]
  13. Breen MS, Kemena C, Vlasov PK, et al. Epistasis as the primary factor in molecular evolution. Nature 2012 ; 490 : 535–538. [CrossRef] [PubMed] [Google Scholar]
  14. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene 2013 ; 32 : 2601–2613. [CrossRef] [PubMed] [Google Scholar]
  15. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012 ; 366 : 1079–1089. [CrossRef] [PubMed] [Google Scholar]
  16. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012 ; 483 : 100–103. [CrossRef] [PubMed] [Google Scholar]
  17. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013 ; 152 : 714–726. [CrossRef] [PubMed] [Google Scholar]
  18. Itzykson R, Kosmider O, Renneville A, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 2013 ; 121 : 2186–2198. [CrossRef] [PubMed] [Google Scholar]
  19. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011 ; 469 : 356–361. [CrossRef] [PubMed] [Google Scholar]
  20. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013 ; 501 : 328–337. [CrossRef] [PubMed] [Google Scholar]
  21. Clappier E, Gerby B, Sigaux F, et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med 2011 ; 208 : 653–661. [CrossRef] [PubMed] [Google Scholar]
  22. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002 ; 100 : 1014–1018. [CrossRef] [PubMed] [Google Scholar]
  23. Klco JM, Spencer DH, Miller CA, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014 ; 25 : 379–392. [CrossRef] [PubMed] [Google Scholar]
  24. Diaz LA, Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014 ; 32 : 579–586. [CrossRef] [PubMed] [Google Scholar]
  25. Krebs MG, Metcalf RL, Carter L, et al. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 2014 ; 11 : 129–144. [CrossRef] [PubMed] [Google Scholar]
  26. Jamal-Hanjani M, Thanopoulou E, Peggs KS, et al. Tumour heterogeneity and immune-modulation. Curr Opin Pharmacol 2013 ; 13 : 497–503. [CrossRef] [PubMed] [Google Scholar]
  27. Jan M, Snyder TM, Corces-Zimmerman MR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012 ; 4 : 149ra118. [PubMed] [Google Scholar]
  28. Solary E, Bernard OA, Tefferi A, et al. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases. Leukemia 2014 ; 28 : 485–496. [CrossRef] [PubMed] [Google Scholar]
  29. Jacobs KB, Yeager M, Zhou W, et al. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet 2012 ; 44 : 651–658. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.